Phathom Pharmaceuticals, Inc. (PHAT): Insider Trading, Congress Trades & Research | Tormere

PHAT

$5.68-1.05%visit website

Phathom Pharmaceuticals, Inc.

Market Cap

$462M

Live price × SEC shares (Oct 27, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

0.63

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Sep 2026 · negative earnings

P/S (TTM)

1.7

TTM to Sep 2026 · revenue

P/B

N/M

TTM to Sep 2026 · negative equity

EV/EBITDA (TTM)

N/M

TTM to Sep 2026 · negative EBITDA

Loading…

Financial Statements

USD thousands	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	Q3 FY2026 Sep 30, 2026	TTM Sep 30, 2026
Revenue	57,584	58,301	74,274	84,722	274,881
Cost of revenue	7,648	11,996	15,096	18,367	53,107
Gross profit	49,936	46,305	59,178	66,355	221,774
Research & development	7,493	7,771	7,813	8,745	31,822
Selling, general & administrative	48,371	54,011	55,330	57,695	215,407
Total operating expenses	55,864	61,782	63,143	66,440	247,229
Operating income	(5,928)	(15,477)	(3,965)	(85)	(25,455)
Interest expense	16,419	15,797	15,103	15,387	62,706
Net income	(21,148)	(30,369)	(17,582)	(13,897)	(82,996)
EPS (basic) ($)		(0.37)	(0.21)	(0.16)	(1.01)
EPS (diluted) ($)		(0.37)	(0.21)	(0.16)	(1.01)
Weighted avg. shares (basic)		82,051	83,747	84,893
Weighted avg. shares (diluted)		82,051	83,747	84,893

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Oct 29, 2026, period ended Sep 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 31 more quarters, back to Mar 2018, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

Frazier Life Sciences Public Fund, L.P. · 2026-11-02

No Form 4 transactions on record.

Recent News

What Phathom Pharmaceuticals Bears Spotted Before A 63% Slide

Yahoo Finance · 2026-11-04

Phathom management has talks scheduled in Boston, New York and London.

Stock Titan · 2026-11-04

Phathom Pharmaceuticals to Participate in November Investor Conferences

Yahoo Finance · 2026-11-04

Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx

Yahoo · 2026-11-03

Phathom Pharmaceuticals Announces $0 Payment From Eligible Commercially Insured Patients For VOQUEZNA Tablets Through BlinkRx

Benzinga · 2026-11-03

How Phathom Pharmaceuticals Inc. (PHAT) Affects Rotational Strategy Timing

Stock Traders Daily · 2026-11-03

H.C. Wainwright reiterates Buy on Phathom stock, $26 target

Investing.com · 2026-10-30

Phathom Pharmaceuticals (NASDAQ:PHAT) Reports 71% Revenue Growth in Q3 2026

Kalkine · 2026-10-30

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

Yahoo · 2026-10-29

Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Yahoo · 2026-10-29

Phathom (PHAT) Q3 2026 Earnings Call Transcript

Yahoo · 2026-10-29

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call Transcript

SeekingAlpha · 2026-10-29

Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates

Yahoo · 2026-10-29

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Yahoo · 2026-10-29

Phathom Pharmaceuticals Q3 2026 Earnings Call Transcript

Benzinga · 2026-10-29

Informational purposes only, not investment advice.

Corporate Events (8-K)

2 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Oct 29, 2026 accepted 7:05 AM ET	2.02Earnings release	Document SEC ↗
Oct 26, 2026 accepted 6:02 AM ET	8.01Other events	Document SEC ↗